Keywords
Coronary Disease ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

138 Search results.

Persönliches Interview SHIP-Trend-1 Herz-Kreislauf-Erkrankungen

- 11/2/17 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: Herz-Kreislauf-Erkrankungen
Herz-Kreislauf-Erkrankungen form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name TREND.TREND1.INT.KHK.KHK. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Liver imaging GSK study Chronic Coronary Heart Disease NCT00799903

- 6/17/20 - 1 form, 11 itemgroups, 60 items, 1 language
Itemgroups: Date of hepatic or liver imaging test, method used for imaging test, images technically adequate, liver size, liver texture, diffuse and/or geographic fatty infiltrate of the liver, Ascites present, Focal Hepatic Lesions characterisable, Gallstones or gallbladder lesions, Biliary ductal lesions, Portal/Hepatic vein abnormalities
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Liver imaging - Repeating form (Unscheduled/Dynamic visit)

Gene Expression Test for Coronary Artery Disease Diagnosis NCT01594411 - Eligibility Criteria

- 7/7/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Primary Care Providers Use of a Gene Expression Test in Coronary Artery Disease Diagnosis; ODM derived from: https://clinicaltrials.gov/show/NCT01594411 This is a prospective, multi-center study examining the clinical impact of the Corus CAD (Age/Sex/Gene Expression score - ASGES) assay in approximately 250 evaluable subjects with no history of obstructive coronary artery disease who now present with chest pain or anginal-equivalent symptoms to a primary care physician (PCP) for evaluation.

Eligibility Coronary Heart Disease NCT02509013

- 3/12/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02509013

Eligibility Coronary Heart Disease NCT02435797

- 3/12/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction; ODM derived from: https://clinicaltrials.gov/show/NCT02435797

Eligibility Coronary Heart Disease NCT02389153

- 3/12/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Feasability of Collaborative Care in the Secondary Prevention of Coronary Heart Disease; ODM derived from: https://clinicaltrials.gov/show/NCT02389153

Eligibility Coronary Heart Disease NCT02044250

- 3/12/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM); ODM derived from: https://clinicaltrials.gov/show/NCT02044250

Eligibility Coronary Heart Disease NCT01735656

- 3/12/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting for True Bifurcation Lesions; ODM derived from: https://clinicaltrials.gov/show/NCT01735656

Eligibility Multiple Conditions NCT01597882

- 1/17/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Improving Monitoring of Patients Receiving Case Management; ODM derived from: https://clinicaltrials.gov/show/NCT01597882

Eligibility Coronary Heart Disease NCT02045134

- 1/15/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery; ODM derived from: https://clinicaltrials.gov/show/NCT02045134

Eligibility Coronary Heart Disease NCT01255540

- 1/15/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
After Eighty Study; ODM derived from: https://clinicaltrials.gov/show/NCT01255540

Pharmacokinetics of an oral contraceptive co-administered with Albiglutide in women - 107032 - Adjudication Events - Heart Failure

- 1/4/19 - 1 form, 15 itemgroups, 86 items, 1 language
Itemgroups: Administrative data, Hospitalization for Heart Failure, Clinical Symptoms of Heart Failure, Investigative Evidence of Structural or Functional Heart Disease, Chest X-Ray, Echocardiography, Left ventricular systolic dysfunction / impairment, Significant valvular heart disease, BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal proBNP), Peak BNP/NT-proBNP value + the laboratory upper reference limit, BNP, NT-proBNP, Other Investigations, Treatment, Description of Event
Study ID: 107032 Clinical Study ID: GLP107032 Study Title: An open-label study to evaluate the pharmacokinetics of an oral contraceptive containing Norethindrone and Ethinyl Estradiol when co-administered with GSK716155 in healthy adult female subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01077505 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: albiglutide Trade Name: Tanzeum,Eperzan Study Indication: Diabetes Mellitus, Type 2